Finished
Clinical Investigation on Feasibility and Usability of the ABLE Exoskeleton Device for Individuals With Spinal Cord Injury to Perform Skills for Home and Community Environments
NCT05643313 · ABLE Human Motion S.L. · Updated 19 Oct 2023
- What is being tested
- ABLE Exoskeleton
- For
- Spinal Cord Injuries
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 70 years. About 10 people. The full rules are on the registry page.
- Where
- Germany, Spain (2 sites)
- When
- Starts or started 25 Nov 2022, ends 28 Aug 2023. Registered 8 Dec 2022.
- Results
- None posted yet.
In the researchers' words
The loss of the ability to walk and the associated restriction of mobility presents a major challenge to people with spinal cord injury in an everyday environment designed for pedestrians. Exoskeletal technology has the potential to help people with impaired leg function to regain ambulation and thus improve their independence. This technology is not completely new, but due to their high access price (\~120k€/unit), high size and weight (\~25 kg), and need for trained physiotherapist supervision, commercially available exoskeletons are only found in large hospitals and only in very few cases get into patients' homes. The company ABLE Human Motion S.L. (Barcelona, Spain) has developed a novel exoskeleton to overcome these disadvantages, which is more compact, lighter and easier to use. The primary objective of this study is to determine the feasibility and usability of the ABLE Exoskeleton for persons with SCI to perform skills in home and community environments.
Sites
- Spinal Cord Injury Center | Heidelberg University HospitalHeidelberg, Germany
- Institut GuttmannBadalona, Barcelona, Spain
